Date	Headline
Apr 25, 2018	PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
Apr 24, 2018	PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
Apr 19, 2018	SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
Apr 18, 2018	PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY
Feb 22, 2018	PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10

Our Contact Form	Mailing Address
Telephone: +1 (866) 594-5999 Fax: +1 (866) 998-0005 info@pvct.com	Provectus Biopharmaceuticals, Inc. 10025 Investment Drive, Suite 250 Knoxville, TN 37932
Investor Relations	Media Relations
Provectus Biopharmaceuticals, Inc. Email: investorrelations@pvct.com Phone: +1 (866) 594-5999 x1	Provectus Biopharmaceuticals, Inc. E-mail: mediarelations@pvct.com Phone: +1 (866) 594-5999 x4
Transfer Agent
(i.e. stockholder records, transfer, change of address, etc.) Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, NY 11717 E-mail: shareholder@broadridge.com Telephone: +1 (877) 830-4936 Fax: +1 (215) 553-5402

Filing Date	Form Type	Description	View
Mar 23, 2018	10-K	Annual report	html pdf xbrl
Nov 08, 2017	10-Q	Quarterly report	html pdf xbrl
Aug 09, 2017	10-Q	Quarterly report	html pdf xbrl
May 10, 2017	10-Q	Quarterly report	html pdf xbrl
Mar 31, 2017	10-K	Annual report	html pdf xbrl

Company Overview